Monte Rosa Therapeutics (GLUE)

Executive Summary

Monte Rosa Therapeutics is a clinical-stage biotech pioneering molecular glue degraders (MGDs) to address historically undruggable targets. Its proprietary QuEEN™ platform enables efficient discovery of degraders against disease-driving proteins. Lead asset MRT-2359 targets MYC-driven cancers (NSCLC, SCLC, etc.) and is in a Phase 1/2 trial with data anticipated in 2H 2026. MRT-8102, a degrader of an undisclosed target for inflammatory diseases, completed Phase 1 enrollment in March 2026 with topline results expected in Q3 2026. The company also completed a Phase 1 study of MRT-6160 in healthy volunteers. With a strong balance sheet and a diversified pipeline, Monte Rosa is well-positioned to validate its platform and drive value in precision oncology and immunology.

Upcoming Catalysts (preview)

• H2 2026MRT-2359 Phase 1/2 interim efficacy data in MYC-driven tumors50% success
• Q3 2026MRT-8102 Phase 1 topline safety and biomarker data in healthy volunteers and elevated CRP60% success
• TBDPotential business development or partnership for QuEEN platform25% success